Molecular Pathology of Myelodysplastic/Myeloproliferative Neoplasms, Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB, and FGFR1, and Mastocytosis
Author:
Hasserjian Robert P.
Reference101 articles.
1. Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML – dysplastic versus proliferative type. Leuk Res. 1998;22(10):871–878.
2. Martiat P, Michaux JL, Rodhain J. Philadelphia-negative (Ph−) chronic myeloid leukemia (CML): comparison with Ph+ CML and chronic myelomonocytic leukemia. The Groupe Francais de Cytogenetique Hematologique. Blood. 1991;78(1):205–211.
3. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood. 1993;82(2):590–599.
4. Haase D, Fonatsch C, Freund M, et al. Cytogenetic findings in 179 patients with myelodysplastic syndromes. Ann Hematol. 1995;70(4):171–187.
5. Cytogenetics of chronic myelomonocytic leukemia. Cancer Genet Cytogenet. 1986;21(1):11–30.